BBLG Relative Valuation
BBLG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BBLG is overvalued; if below, it's undervalued.
Historical Valuation
Bone Biologics Corp (BBLG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.54. The fair price of Bone Biologics Corp (BBLG) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.57
Fair
-0.96
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Bone Biologics Corp. (BBLG) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Bone Biologics Corp. (BBLG) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is -0.41. The thresholds are as follows: Strongly Undervalued below -3.26, Undervalued between -3.26 and -1.83, Fairly Valued between 1.01 and -1.83, Overvalued between 1.01 and 2.44, and Strongly Overvalued above 2.44. The current Forward EV/EBIT of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Bone Biologics Corp. (BBLG) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Bone Biologics Corp. (BBLG) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Bone Biologics Corp. (BBLG) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Bone Biologics Corp (BBLG) has a current Price-to-Book (P/B) ratio of 0.46. Compared to its 3-year average P/B ratio of 0.66 , the current P/B ratio is approximately -30.38% higher. Relative to its 5-year average P/B ratio of 0.89, the current P/B ratio is about -48.33% higher. Bone Biologics Corp (BBLG) has a Forward Free Cash Flow (FCF) yield of approximately -120.44%. Compared to its 3-year average FCF yield of -259.53%, the current FCF yield is approximately -53.59% lower. Relative to its 5-year average FCF yield of -186.34% , the current FCF yield is about -35.36% lower.
0.46
P/B
Median3y
0.66
Median5y
0.89
-120.44
FCF Yield
Median3y
-259.53
Median5y
-186.34
Competitors Valuation Multiple
The average P/S ratio for BBLG's competitors is 0.30, providing a benchmark for relative valuation. Bone Biologics Corp Corp (BBLG) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BBLG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BBLG in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Bone Biologics Corp (BBLG) currently overvalued or undervalued?
Bone Biologics Corp (BBLG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.54. The fair price of Bone Biologics Corp (BBLG) is between to according to relative valuation methord.
What is Bone Biologics Corp (BBLG) fair value?
BBLG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bone Biologics Corp (BBLG) is between to according to relative valuation methord.
How does BBLG's valuation metrics compare to the industry average?
The average P/S ratio for BBLG's competitors is 0.30, providing a benchmark for relative valuation. Bone Biologics Corp Corp (BBLG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Bone Biologics Corp (BBLG) as of Jan 07 2026?
As of Jan 07 2026, Bone Biologics Corp (BBLG) has a P/B ratio of 0.46. This indicates that the market values BBLG at 0.46 times its book value.
What is the current FCF Yield for Bone Biologics Corp (BBLG) as of Jan 07 2026?
As of Jan 07 2026, Bone Biologics Corp (BBLG) has a FCF Yield of -120.44%. This means that for every dollar of Bone Biologics Corp’s market capitalization, the company generates -120.44 cents in free cash flow.
What is the current Forward P/E ratio for Bone Biologics Corp (BBLG) as of Jan 07 2026?
As of Jan 07 2026, Bone Biologics Corp (BBLG) has a Forward P/E ratio of -0.96. This means the market is willing to pay $-0.96 for every dollar of Bone Biologics Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bone Biologics Corp (BBLG) as of Jan 07 2026?
As of Jan 07 2026, Bone Biologics Corp (BBLG) has a Forward P/S ratio of 0.00. This means the market is valuing BBLG at $0.00 for every dollar of expected revenue over the next 12 months.